Sensiva Health has filed a patent application that allows for risk stratification for contagious diseases using a proprietary algorithm that incorporates available diagnostics and future vaccination data. The company hopes to use this data to minimize the impact of reinfection and allow patients to return to work or other social interactions. The company hopes this will be an essential first step in its mission to improve the lives of millions of people. But how do they plan to accomplish this goal?
Sensiva’s COVID-19 test was approved by the FDA.
The company has a high-volume CLIA-certified medical lab and an IT platform that supports the rapid production and delivery of its COVID-19 test. The company plans to scale its production and delivery capacity for COVID-19 quickly. It expects to achieve this goal within 45 days. It has already received approval for this test from the FDA. The company intends to manufacture, deliver, and process over 100,000 tests per week.
In addition to the COVID-19 PCR+Antigen/Antibody Test, Sensiva has a patent application that covers the innovative approach to risk stratification in the testing process. Its proprietary algorithm uses public health data, vaccine and diagnostics data to identify patients with a high risk for reinfection. As a result, Sensiva’s COVID-19 PCR+Antibody Test is the first non-prescription COVID-19 testing solution.
Sensiva’s new Maple Grove facility
In the past, Sensiva relied on a small private cloud provider that did not have the flexibility or scalability to accommodate its growing workload. Its COVID-19 test, which is authorized by the U.S. Food and Drug Administration (FDA), required a 24-hour turnaround. The private cloud provider also had numerous system issues and outages. As a result, Sensiva is moving to a new facility to handle increasing demand.
Cloudera helps Sensiva move to Amazon Web Services.
As an AWS Premier Partner, Cloudnexa is a trusted resource for companies looking to make the switch to AWS. Previously, Cloudnexa helped One Medical Passport migrate to AWS. Now, Cloudnexa is helping Sensiva Health migrate to AWS to process COVID-19 test kits. With the help of Cloudnexa, Sensiva can handle all the challenges of COVID-19 processing while remaining HIPAA compliant.
Previously, Sensiva relied on a private cloud provider that was not flexible enough for their needs. With COVID-19 testing, approved by the U.S. Food and Drug Administration and Cormeum Laboratory Services, Sensiva needed to process results within 24 hours.
